EHang Holdings (EH) Is Down 5.3% After Announcing Hefei VT35 Hub Partnership and Updated Guidance

• In August 2025, EHang Holdings announced a new partnership with the Hefei government to build a comprehensive hub for its VT35 pilotless eVTOL aircraft, backed by approximately RMB 1 billion in total investment and RMB 500 million in government support, along with updated 2025 revenue guidance and quarterly earnings results.
• This collaboration marks a significant step for EHang in industrializing its next-generation aircraft with municipal support, potentially accelerating wider adoption of autonomous air mobility solutions in East China.
• We'll consider how EHang's investment agreement with Hefei and plans for VT35 production may influence its overall investment narrative.

Rare earth metals are the new gold rush. Find out which 29 stocks are leading the charge.

EHang Holdings Investment Narrative Recap

To be a shareholder in EHang, you need confidence in the potential for urban air mobility to transform city infrastructure, and a belief that government partnerships can drive practical deployment of pilotless eVTOL technology. The recent Hefei agreement, with its government backing and renewed focus on VT35 production, may accelerate operational ramp-up, but does not materially reduce near-term risks such as slower revenue growth or execution delays resulting from the company’s lowered 2025 guidance and prioritization of readiness over short-term deliveries.

EHang’s announcement revising its 2025 revenue guidance to RMB 500 million is particularly relevant, signaling a more measured approach to commercialization even as expansion plans in Hefei ramp up. This recalibration continues to make operational execution and regulatory milestones key near-term catalysts, while putting added emphasis on the importance of government partnerships like Hefei to support scaling ambitions.

By contrast, the interplay between slower revenue delivery and ongoing high expenses remains a critical factor that investors should be aware of...

Read the full narrative on EHang Holdings (it's free!)

EHang Holdings' narrative projects CN¥2.0 billion revenue and CN¥337.4 million earnings by 2028. This requires 68.4% yearly revenue growth and a CN¥581.9 million increase in earnings from CN¥-244.5 million today.

Uncover how EHang Holdings' forecasts yield a $25.55 fair value, a 64% upside to its current price.

Exploring Other Perspectives

Fifteen individual fair value estimates from the Simply Wall St Community range from CN¥4.95 to CN¥372.95, with most falling well below analyst consensus. Despite this divergence, municipal support and revised revenue guidance continue to shape expectations for EHang’s performance. Explore the range of community perspectives for a fuller view of the opportunity and its risks.

Explore 15 other fair value estimates on EHang Holdings - why the stock might be worth less than half the current price!

Build Your Own EHang Holdings Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your EHang Holdings research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free EHang Holdings research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate EHang Holdings' overall financial health at a glance.

Looking For Alternative Opportunities?

These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

• Find companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 29 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com